Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 20;31(12):8054-8074.
doi: 10.3390/curroncol31120594.

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications

Fulvio Borella  1 , Stefano Fucina  1 , Ylenia Seminara  1 , Pietro Denti  1 , Domenico Ferraioli  2 , Luca Bertero  3 , Niccolò Gallio  4 , Jessica Cusato  5 , Giorgio Valabrega  6 , Alberto Revelli  4 , Luca Marozio  1 , Stefano Cosma  1
Affiliations
Review

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications

Fulvio Borella et al. Curr Oncol. .

Abstract

The enzyme topoisomerase II alpha (TOP2A) plays a critical role in DNA replication and cell proliferation, making it a promising target for cancer therapy. In epithelial ovarian cancer (EOC), TOP2A overexpression is associated with poor prognosis and resistance to conventional treatments. This review explores the biological functions of TOP2A in EOC and discusses its potential as a therapeutic target. We highlight studies on the mechanisms through which TOP2A contributes to tumor progression and recurrence. Additionally, we evaluate the clinical implications of targeting TOP2A, including the use of TOP2A inhibitors and their combination with novel drugs. We provide a comprehensive overview of the current understanding and future directions for targeting TOP2A in the management of EOC.

Keywords: PARPi; TOP2A; anthracyclines; doxorubicin; etoposide; immune checkpoint inhibitors; ovarian cancer; topoisomerase.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Relationship between TOP2A overexpression and epithelial ovarian cancer.
Figure 2
Figure 2
Different interactions of etoposide and doxorubicin with TOP2A. Figure adapted from the paper by Van Ravenstein et al. [54].
See this image and copyright information in PMC

References

    1. Bray F., Laversanne M., Sung H., Ferlay J., Siegel R.L., Soerjomataram I., Jemal A. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2024;74:229–263. doi: 10.3322/caac.21834. - DOI - PubMed
    1. Lheureux S., Gourley C., Vergote I., Oza A.M. Epithelial Ovarian Cancer. Lancet. 2019;393:1240–1253. doi: 10.1016/S0140-6736(18)32552-2. - DOI - PubMed
    1. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., Mannel R.S., Homesley H.D., Fowler J., Greer B.E., et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N. Engl. J. Med. 2011;365:2473–2483. doi: 10.1056/NEJMoa1104390. - DOI - PubMed
    1. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., Carey M.S., Beale P., Cervantes A., Kurzeder C., et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N. Engl. J. Med. 2011;365:2484–2496. doi: 10.1056/NEJMoa1103799. - DOI - PubMed
    1. Ledermann J.A., Raja F.A., Fotopoulou C., Gonzalez-Martin A., Colombo N., Sessa C. Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2013;24:vi24–vi32. doi: 10.1093/annonc/mdt333. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources